The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Two construction workers were found unconscious and later pronounced dead in a Manhattan apartment stairwell. The cause is ...

Weill Cornell Medicine has secured a grant of approximately $4m for a trial to assess a new imaging approach in prostate ...

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

The federal criminal trial of Sean "Diddy" Combs got underway with opening statements Monday morning shortly after the final jury pool was seated ... and we've got details about the ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

One of the victims, a 34-year-old man, died at the scene inside the stairwell on Mulberry St. near Hester St. about 3:45 p.m.

Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

In secondary endpoints, 64.6% of participants using Zepbound saw 15% weight loss compared with 40.1% on Wegovy. And Zepbound participants saw their waists reduced by an average 7.2 in (18.4 cm), ...

At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk's own treatment, Eli Lilly said of the results presented at the European Congress ...

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines. Zepbound won on ...